Trial Profile
A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl(R) (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2015
Price :
$35
*
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Hyperammonaemia
- Focus Adverse reactions
- Sponsors Hyperion Therapeutics
- 26 Jun 2014 New trial record